GLP-1R Agonist Salt Crystal Forms for Solid-State Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GLP-1R receptor agonist compounds exhibit poor stability and unsatisfactory solid properties, prone to change under conditions such as grinding, compressing, or high humidity, which affects their medicinal processability.
Innovation Solution
Development of 2-amino-2-(hydroxymethyl)-1,3-propanediol salts and solvates of the GLP-1R receptor agonist compounds, specifically in crystal forms A, B, C, D, and E, which exhibit improved stability and solid properties, including specific X-ray diffraction patterns and thermal stability profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the GLP-1R receptor agonist compound is used in its original form, then it can treat metabolism-related diseases, but it exhibits poor stability and unsatisfactory solid properties under room temperature or high-temperature conditions
Solution Approach 1:
The patent applies parameter changes by converting the original compound into different salt forms (sodium salt, potassium salt, calcium salt, ammonium salt) and solvate forms (monohydrate, dihydrate). These chemical parameter changes fundamentally alter the stability and solid properties of the compound, transforming it from an unstable form to stable crystalline forms suitable for pharmaceutical manufacturing and storage.
Solution Approach 2:
The patent creates composite material structures by forming salts and solvates of the GLP-1R agonist compound. These composite forms combine the active pharmaceutical ingredient with counterions (Na+, K+, Ca2+, NH4+) and solvent molecules (water) in specific crystal lattices, resulting in materials with enhanced stability and improved solid properties while maintaining the therapeutic activity of the original compound.
2Ease of manufacture
If the compound undergoes grinding, compressing, or mixing processes, then it can be prepared for medicinal use, but the stability and crystal form of the compound are prone to change
Solution Approach 1:
The patent applies beforehand cushioning by pre-stabilizing the compound through salt and solvate formation before the compound undergoes manufacturing processes. The stable crystal structures of these salt and solvate forms act as a protective framework that cushions against the destabilizing effects of grinding, compressing, and mixing, preventing unwanted crystal form changes and maintaining composition stability throughout the medicinal preparation process.
3Productivity
If high-temperature conditions are applied, then processing efficiency is improved, but the compound exhibits poor stability
Solution Approach 1:
The patent applies parameter changes by transforming the compound into salt and solvate forms that possess higher thermal stability parameters. These modified forms can withstand elevated temperatures during processing without decomposing or losing stability, thereby enabling high-temperature processing operations that improve productivity while maintaining compound integrity and reliability.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Disclosed in the present invention are a GLP-1R receptor agonist compound salt and a crystal form thereof, a preparation method therefor and a use thereof. Specifically, disclosed is a 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of a compound of formula I or a solvate thereof. The 2-amino-2-(hydroxymethyl)-1,3-propanediol salt of the compound of formula I or the solvate thereof provided by the present invention has good crystal form stability and good medicinal prospects.